← Back to all signals
RESEARCH PAPER ANALYSIS

Strategy of adult thalamic glioma surgery: Thoughts and practices based on thalamic glioma classification.

AI interpretation is pending for this paper.

Open original publication →
PMID41609920
JournalNeurosurgical review
Publication Date2026-01-29
Ingested2026-08-02 12:06 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

Adult thalamic gliomas (ATGs) present a significant surgical challenge due to their deep location and proximity to critical brain structures. To standardize the surgical approaches, we proposed a novel anatomically-guided classification that divides thalamic gliomas into four distinct zones, each associated with specific surgical approaches. This retrospective study included 201 patients (median age 40 years) with WHO grade 2–4 thalamic gliomas treated at West China Hospital from 2012 to 2024. Utilizing two vertical lines transecting the internal capsule genu and the third ventricle midpoint, we categorized thalamic gliomas into Zone I (anterolateral), Zone II (posterolateral), Zone III (dorsomedial), and Zone IV (ventromedial). Survival analysis was performed using multivariable Cox regression with bidirectional stepwise selection, Kaplan–Meier analysis and log-rank testing. Intervariable associations were quantified using Cramer's V. Tumors invading multiple zones were the most frequent, representing 23.88% of cases, whereas only 1.98% involved both cerebral hemispheres. Supra-tentorial lateral approaches were most commonly employed (51.4%), and no patients required a supracerebellar infratentorial approach. Median overall survival was 10 months. After adjusting for molecular markers, adjuvant therapy and WHO grading, extent of resection (EOR) remained an independent prognostic factor (vs. gross total resection: subtotal HR = 1.62, p = 0.04; partial HR = 1.87, p < 0.001). Surgical approach significantly correlated with EOR in Zones I + II and II + III (p < 0.05), while Zones IV and III + IV demonstrated strong effect sizes (Cramer's V = 0.516 and 0.356, respectively), although these associations did not reach statistical significance. Maximal safe resection is a clinically justified first-line treatment for ATG patients. The transcallosal anterior approach is recommended for midline tumors located in Zones III, IV, or III + IV, particularly in cases involving obstructive hydrocephalus. For posterolateral tumors in Zones II and II + III, the approach should be determined by the direction of tumor extension. Nevertheless, further research with larger sample sizes is warranted to refine and optimize treatment strategies for thalamic gliomas. Clinical trial number: not applicable.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 [Nontuberculous mycobacterial infections in patients with hematologic diseases]. [Rinsho ketsueki] The Japanese journal of clinical hematology 64.4 2 [Fundamentals of genetic counseling in hematology: pedigree construction and management of secondary findings in HemeSight®]. [Rinsho ketsueki] The Japanese journal of clinical hematology 49.9 3 Uncovering LINC02982: a T-ALL-specific lncrna linking epigenetic regulation and metabolic pathways. Cancer cell international 51.9 4 Knowledge and awareness of oral cancer and precancerous lesions among patients attending Dhaka Dental College Hospital: a cross-sectional study. BMC oral health 66.4 5 Changes in Body Weight Percentile During Primary Anticancer Treatment in Children: A Retrospective Single-Center Study. Cureus 64.74 6 Erratum: Addition of Rituximab to First-Line Treatment of Burkitt Lymphoma in Children and Young Adults in Tanzania: A Cost-Utility Analysis. JCO global oncology 50.74 7 Subclonal AGGF1::PDGFRB rearrangement in a myelodysplastic/myeloproliferative neoplasm with suboptimal response to imatinib. American journal of clinical pathology 62.42 8 Trachea, bronchus, and lung cancer in women of reproductive age: global burden trends from 1990 to 2021 and forecasts to 2035. Frontiers in global women's health 38.5 9 From missed diagnosis to lifelong survivorship: a precision oncology roadmap for equity in pediatric and AYA cancer care. Frontiers in oncology 61.8 10 Genomic rearrangements define a distinct biological state in neuroblastoma. Cancer genetics 57.2 11 Clinical characteristics and treatment outcomes of neuroblastoma with pulmonary metastases. World journal of pediatric surgery 71.44 12 A rare cause of dysphagia: A case report on gastroesophageal adenocarcinoma in childhood. JPGN reports 51.9 13 Patterns of high-risk histopathology features of retinoblastoma in enucleated and exenterated eyes at Tikur Anbessa Specialized Hospital: a retrospective study. Cancer treatment and research communications 67.9 14 Pediatric cancer and ethical decision-making: Who speaks for the child? Journal of pediatric nursing 65.3 15 Diagnostic evaluation of long-read nanopore sequencing for pediatric CNS tumors. Acta neuropathologica communications 57.5 16 Preventive Immunomodulatory Effects of Doxycycline and Hyperbaric Oxygen Therapy on Serum Tumor Necrosis Factor-α and Interleukin-6 Levels in a Rat Model of Malaria. Journal of parasitology research 58.44 17 Persistent Pediatric Cervical Lymphadenopathy: A Case Report of Kikuchi-Fujimoto Disease Mimicking Infection and Malignancy. Case reports in pediatrics 50.2 18 Cementoblastoma With Bony and Soft Tissue Recurrences Following a Primary Molar Lesion: A Case Report. Case reports in dentistry 47.5 19 Global, Regional, and National Trends of Pediatric Soft Tissue and Other Extraosseous Sarcomas, 1990 to 2021: A GBD Study. Journal of pediatric hematology/oncology 60.4 20 Breaking the Barrier: MBI-LCBI and Recent Beta-lactam Exposure as Predictors of Piperacillin-Tazobactam Resistance in Pediatric Hemato-oncology Patients. The Pediatric infectious disease journal 69.4 21 Exploiting iron metabolism in Ewing sarcoma. Communications medicine 64.2 22 Unusual [18F]FDOPA PET-CT maging of insulinomas in children. EJNMMI reports 53.0 23 Spontaneous inversion of the left atrial appendage: a first autopsy case report and updated literature review. Cardiology in the young 45.5 24 Prognostic significance of end-of-induction measurable residual disease below 0.01% in pediatric B-lineage acute lymphoblastic leukemia. Cytometry. Part B, Clinical cytometry 65.8 25 Multiple Exposures to Antibiotics Affect Tumor Development in a Mouse Model of Early-Onset Colorectal Cancer. Carcinogenesis 50.9 26 Population-Based Assessment of Cardiometabolic Late Effects in 5-Year Survivors of Pediatric Acute Lymphoblastic Leukemia. Pediatric blood & cancer 69.2 27 Circulating Biomarkers of Disease Burden in Patients With Relapsed or Refractory Neuroblastoma Treated With 131I-MIBG Therapy: A Report From the New Approaches to Neuroblastoma Therapy Consortium. Pediatric blood & cancer 85.43 28 Venetoclax as Salvage Treatment for Relapsed/Refractory B-ALL Post-CAR-T Therapy. Pediatric blood & cancer 82.0 29 Surgical Margin and Risk of Local Recurrence in Children and Young Adults With Nonrhabdomyosarcoma Soft Tissue Sarcoma: A Nonrandomized Clinical Trial. JAMA surgery 86.8 30 Enzyme-functionalized β-cyclodextrin silicasomes for sequential stroma remodeling and combination chemotherapy in neuroblastoma. Journal of materials chemistry. B 61.64 31 Undescended Testes in Medically Complex Children: Evaluating A Common Urologic Condition Through a Multi-Disciplinary Lens. The Journal of urology 59.5 32 Brain-sensing synNotch-CAR T cells enable precise targeting and clearance of diffuse midline glioma in multiple preclinical models. Science translational medicine 66.0
PATIENT-FRIENDLY SUMMARY

Strategy of adult thalamic glioma surgery: Thoughts and practices based on thalamic glioma classification.

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic